Broncus Holding Corp. (HK:2216)
:2216
Want to see HK:2216 full AI Analyst Report?
2216 Stock Chart & Stats
HK$2.36
HK$0.01(1.61%)
At close: 4:00 PM EST
HK$2.36
HK$0.01(1.61%)
Day’s Range― - ―
52-Week RangeHK$0.69 - HK$3.72
Previous CloseN/A
Volume341.00K
Average Volume (3M)2.03M
Market Cap
HK$401.84M
Enterprise ValueHK$34.61M
Total Cash (Recent Filing)HK$69.24M
Total Debt (Recent Filing)HK$16.00K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding528,737,060
10 Day Avg. Volume1,907,700
30 Day Avg. Volume2,030,864
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.99
Price to Sales (P/S)850.02
P/FCF Ratio-14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low-debt capital structure and positive equity reduce near-term refinancing risk and provide a financial runway. Over the next 2–6 months this durability allows the company to fund operations, R&D or commercialization efforts without immediate pressure to raise dilutive capital, supporting strategic optionality while it stabilizes revenues.
Niche Interventional Pulmonology FocusA focused product set in interventional pulmonology creates a durable competitive position: specialized clinical applications, higher switching costs, and long adoption cycles mean that successful devices can sustain revenue once traction returns. This specialization supports targeted sales and clinical relationships over the medium term.
Improving Free Cash Flow TrendA less-negative free cash flow in the latest year suggests operational stabilization versus prior periods. If the trend persists, it reduces near-term external funding needs and signals management progress on cost structure or revenue recovery, which materially improves survivability and strategic flexibility over the coming months.
Bears Say
Severe Revenue CollapseA near-total revenue collapse indicates a major loss of commercial traction or product access. Such a structural decline undermines economies of scale, jeopardizes customer relationships and distribution, and makes medium-term revenue recovery challenging without clear product or market remediation, constraining operational planning.
Persistent Cash BurnConsistent negative operating and free cash flow forces dependence on external financing or equity raises. Even with low leverage, ongoing cash consumption limits ability to invest in commercialization or R&D, increases dilution risk, and constrains the company’s capacity to execute a sustainable recovery plan within months.
Sustained Operating And Net LossesChronic unprofitability and negative margins show the business is not yet self-sustaining. Continued losses depress returns on equity and reduce reinvestment capacity, meaning management must either materially improve revenue/margins or continue external funding—both difficult to achieve quickly in a capital-intensive medical device market.
Broncus Holding Corp. News
2216 FAQ
What was Broncus Holding Corp.’s price range in the past 12 months?
Broncus Holding Corp. lowest stock price was HK$0.69 and its highest was HK$3.72 in the past 12 months.
What is Broncus Holding Corp.’s market cap?
Broncus Holding Corp.’s market cap is HK$401.84M.
When is Broncus Holding Corp.’s upcoming earnings report date?
Broncus Holding Corp.’s upcoming earnings report date is Aug 27, 2026 which is in 74 days.
How were Broncus Holding Corp.’s earnings last quarter?
Currently, no data Available
Is Broncus Holding Corp. overvalued?
According to Wall Street analysts Broncus Holding Corp.’s price is currently Overvalued.
Does Broncus Holding Corp. pay dividends?
Broncus Holding Corp. does not currently pay dividends.
What is Broncus Holding Corp.’s EPS estimate?
Broncus Holding Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Broncus Holding Corp. have?
Broncus Holding Corp. has 528,737,060 shares outstanding.
What happened to Broncus Holding Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Broncus Holding Corp.?
Currently, no hedge funds are holding shares in HK:2216
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Broncus Holding Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Broncus Holding Corp.
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
Technical Analysis
MicroPort Scientific
―
Vincent Medical Holdings Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Rainmed Medical Limited
―
Options Prices
Currently, No data available
---